Blog - Page 16 of 5405 - QualityStocks

FridayJul 18, 2025 3:00 pm

QualityStocksNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Charts Dual-Path for NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. “The company recently filed an application under the newly created FDA Commissioner’s National Priority Voucher (‘CNPV’) program, which promises significantly shortened review timelines for drugs that meet urgent U.S. health priorities,” reads an article discussing NRx. “In parallel, the company has filed an Abbreviated New Drug Application (‘ANDA’) for NRX-100 with a request for priority review. The two pathways, CNPV and ANDA, are expected to complement one another. Should the…

FridayJul 18, 2025 11:43 am

QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Expands Indo-Pacific Defense Role With New U.S. Government Contractor Order

Safe Pro Group (NASDAQ: SPAI), an AI-driven defense and security solutions provider, received a new order from a U.S. Government Contractor supporting Department of State demining operations in the Indo-Asia Pacific region. Scheduled for Q3 2025 delivery, the order includes ballistic and Explosive Ordnance Disposal (EOD) protective equipment. Safe Pro will also deploy and demonstrate its proprietary SpotlightAI(TM) drone-based computer vision platform for landmine detection. Following passage of the $30 billion One Big Beautiful Bill Act (OBBBA), the Company is expanding to support the U.S. Indo-Pacific Command (USINDOPACOM) and plans broader integration of its SPOTD threat detection technology with military…

FridayJul 18, 2025 10:30 am

D-Wave Quantum Inc. (NYSE: QBTS) Secures $400 Million in Equity Offering, Eyes Acquisitions and Expansion

The $400M at-the-market equity offering was completed in just over two weeks. The average sale price in the offering was at a 149% premium compared to the company’s previous ATM raise in January 2025. The company holds a cash balance of approximately $815 million as of July 1. Proceeds will support strategic acquisitions, capital expenditures, and working capital needs. The ATM program comes as D-Wave’s Q1 2025 revenue surged 509% year-over-year, boosted by a major system sale to Germany’s Julich Supercomputing Center. D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has completed sales…

FridayJul 18, 2025 10:20 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sets Key Dates for 25% Preferred Stock Dividend

Nutriband (NASDAQ: NTRB) is reminding shareholders of its upcoming 25% preferred stock dividend. Shareholders of record as of July 25, 2025, will receive one preferred share for every four common shares held, with the dividend payable on August 5. Each preferred share will be convertible to one common share upon FDA approval of Nutriband’s AVERSA Fentanyl product. Unconverted preferred shares will be eligible for annual cash dividends from company profits at the discretion of the board. To view the full report, visit https://ibn.fm/LsLzM About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products.…

FridayJul 18, 2025 9:45 am

ONAR Holding Corp. (ONAR): A Strategic Pivot Toward Scalable, High-Margin Growth

ONAR’s 79% year-over-year revenue growth in Q1 2025 reflects its strategic shift toward high-value, recurring marketing services Recent restructuring and brand consolidation positions ONAR as a focused, technology-enabled marketing platform In an environment where digital ad spending is increasingly scrutinized for return on investment, many mid-sized companies face a dilemma: how to achieve measurable marketing results without access to enterprise-level tools or sprawling internal teams. This challenge is growing in urgency as the advertising landscape becomes more fragmented, data-driven, and AI-powered. ONAR Holding Corp. (OTCQB: ONAR) is positioning itself squarely at the intersection of this need. By combining specialty marketing…

FridayJul 18, 2025 9:15 am

QualityStocksNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Details Veloce Investment and Quadrant Acquisition in Motorsport Expansion Push

SEGG Media (NASDAQ: SEGG, LTRYW), released further details on its strategic investment in Veloce Media Group, including Veloce’s July 12, 2025 acquisition of Quadrant, a motorsport and content brand co-founded by Formula 1 driver Lando Norris. Funded by the initial tranche of SEGG’s $7.59 million subscription agreement, the deal gives SEGG a 12.4% stake in Veloce and the option to increase to 51% ownership. With Veloce reporting $17.5 million in FY2024 revenue and 750 million monthly digital views, and Quadrant bringing strong brand equity and shareholders like Zak Brown and Adrian Newey, SEGG positions itself for high-growth dominance in digital…

FridayJul 18, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial

Recent data indicates Soligenix’s HyBryte(TM) is showing promising treatment success in early-stage cutaneous T-cell lymphoma. “With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” leading investigator states. No new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks. Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study…

FridayJul 18, 2025 9:00 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company focused on treating brain and CNS cancers, will implement a 1-for-12 reverse stock split effective July 22, 2025. Its common stock will continue trading under the symbol CNSP but with a new CUSIP number: 18978H508. Each 12 shares of common stock will convert into one, with proportional adjustments to warrants and equity awards. No fractional shares will be issued—holders will receive cash instead. The authorized share count will be reduced to 25 million, while par value remains $0.001. The move is designed to affect all shareholders uniformly. To view the full press release,…

ThursdayJul 17, 2025 10:30 am

Brera Holdings PLC (NASDAQ: BREA) Offers Investors a New Path to Pro Sports Ownership

Family offices, privately held wealth management firms for affluent families, are increasingly investing in sports franchises, seeing them as long-term assets with legacy-building potential. Brera Holdings attracted eight family offices in its recent Series A Preferred Offering, reflecting growing institutional interest, but Brera also offers retail investors access to pro sports – once the domain of billionaires and celebrities. With a Nasdaq listing, Brera is the first multi-club operator to offer public equity exposure to professional football clubs. Brera’s Juve Stabia club saw a 245% increase in market value over the 2024–25 season, driven by competitive performance. Brera Holdings (NASDAQ:…

ThursdayJul 17, 2025 10:20 am

QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) Announces Strategic Partnership and Intent to Acquire BioSpark AI to Advance Drug Repurposing

Fifty 1 Labs (OTC: FITY) announced a strategic partnership and intent to acquire Vancouver-based BioSpark AI Technologies Inc., a leader in AI and large language model technologies. The alliance merges BioSpark’s literature mining platform with Fifty1’s predictive modeling to extract real-world clinical insights at scale—unlocking overlooked therapeutic patterns for drug repurposing. The partnership will support rapid identification of new formulations focused on performance health and preventative care, with proprietary delivery systems. The move reinforces Fifty1 AI Labs’ vision to lead in AI-powered functional medicine by integrating structured clinical data with advanced Bayesian inference and human-AI collaboration. To view the full…

Site Search

Company Search